跳至主導覽 跳至搜尋 跳過主要內容

Precision Medicine in Cholangiocarcinoma: Past, Present, and Future

  • Chi Yuan Cheng
  • , Chiao Ping Chen
  • , Chiao En Wu*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital

研究成果: 期刊稿件 › 文獻綜述 › 同行評審

17 引文 斯高帕斯(Scopus)

摘要

Cholangiocarcinoma (CCA), or biliary tract cancer, has a poor prognosis. The median survival time among patients with CCA is under 2 years from diagnosis, and the global 5-year survival rate is only 10%. First-line therapy with chemotherapeutic agents, gemcitabine plus cisplatin, has traditionally been used to treat unresectable advanced CCA. In recent years, precision medicine has become a mainstream cancer treatment due to innovative next-generation sequencing technology. Several genetic alterations, including mutations, gene fusions, and copy number variations, have been found in CCA. In this review, we summarized the current understanding of genetic profiling in CCA and targeted therapy in CCA. Owing to the high heterogeneity of CCA, tumor microenvironmental factors, and the complexity of tumor biology, only pemigatinib, infigratinib, ivosidenib, larotrbctinib, and entrectinib are currently approved for the treatment of CCA patients with fibroblast growth factor receptor 2 gene (FGFR2) fusion, isocitrate dehydrogenase gene (IDH1) mutation, and neu-rotrophin receptor tyrosine kinase gene (NRTK) fusion, respectively. Additional targeted therapies, including other FGFR2 inhibitors, PI3K/AKT/mTOR inhibitors, and BRAF-directed targeted therapy, have been discussed for the management of CCA, and immune checkpoint inhibitors, particularly pembrolizumab, can be administered to patients with high microsatellite instability tumors. There is a further need for improvement in precision medicine therapies in the treatment of CCA and discuss the approved and potential targeted therapies for CCA.

原文英語
文章編號829
期刊Life
卷12
發行號6
DOIs
出版狀態已出版 - 06 2022
對外發佈是

文獻附註

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Precision Medicine in Cholangiocarcinoma: Past, Present, and Future」主題。共同形成了獨特的指紋。

引用此